Cost-Effectiveness of Extracorporeal Photopheresis for the Treatment of Patients With Erythrodermic (Stage T4, M0) Cutaneous T-Cell Lymphoma in the Australian Setting

Peacock, A; Dehle, F; Mesa Zapata, OA; Prince, HM; Gennari, F; Taylor, C

Author(s): Peacock, A; Dehle, F; Mesa Zapata, OA; Prince, HM; Gennari, F; Taylor, C;
Details: Publication Year 2022-06,Volume 25,Issue #6,Page 965-974
Journal Title: Value in Health
Publication Type: Research article
Abstract: OBJECTIVES: Cutaneous T-cell lymphoma (CTCL) is a rare and incurable disease, and patients currently experience a lack of treatment options in Australia. This analysis evaluated the cost-effectiveness of extracorporeal photopheresis (ECP) compared with standard of care therapy for the treatment of patients with erythrodermic (stage T(4), M(0)) CTCL, who are refractory to previous systemic treatment. METHODS: A Markov model was developed from the perspective of the Australian government. Health states were treatment specific and transition probabilities were modeled from time-to-next-treatment data from a published Australian observational study of ECP and comparator treatments. Quality of life utility values were based on psoriasis as a proxy for CTCL, which was validated by consultation with local clinicians. The time horizon for the model was 5 years. The ECP treatment regimen was compared with a weighted treatment comparator based on results of a treatment survey and Australian prescribing data. RESULTS: ECP as a second-line treatment option for CTCL was less costly and more effective than other treatment strategies. ECP had an average cost saving of $37 592 and incremental quality-adjusted life-year gained of 0.20 to 0.21, attributed to patients being able to better tolerate ECP thus avoiding subsequent treatment with high-cost alternatives. CONCLUSIONS: This is the first published cost-utility analysis of ECP for CTCL. This analysis demonstrates that ECP is a cost-effective option for the treatment of patients with erythrodermic CTCL in Australia.
Keywords: Australia; Cost-Benefit Analysis; Humans; *Lymphoma, T-Cell, Cutaneous/etiology/pathology/therapy; *Photopheresis/adverse effects/methods; Quality of Life; *Skin Neoplasms/etiology/therapy; cost-effectiveness; cost-utility; cutaneous T-cell lymphoma; extracorporeal photopheresis
Department(s): Haematology
PubMed ID: 35667784
Publisher's Version: https://doi.org/10.1016/j.jval.2021.11.1364
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-02-14 06:28:02

Last Modified: 2025-02-14 06:31:35